GREY:RPBIF - Post by User
Post by
HippygirL74on Jun 26, 2008 9:53pm
325 Views
Post# 15235537
Conference call highlights
Conference call highlights3M has launched FluA FluB in Australia and New Zealand and 3M will launch same for North America in fall 2008 (that's only 10 weeks from now). The RSV test ,they stated, is a very large market and complimentary to the Flu tests.
Roche will need 2 quarters to prepare for the launch of the cardiac line. There is no equity investment from Roche- CEO Wayne said that an equity investment would discount the share price so instead a strong "transfer price" is used instead.
He mentioned that if RBM was ever sold, this method would give increased long-term value. ( i find it interesting that the mention of RBM for sale was brought up- therefore, some thought is already in the cards for this possibility)
Roche sets their selling price and RBM has a set transfer price. As far as minimum sales and targets, that is confidential. Lots of confidential things.
CEO Wayne talked about huge growth but did not mention when the company would be cash flow positive.
He said that Roche has $9 Billion/year in sales in diagnostics globally.
He said that Biosite has the least penetration in the 18,000 CLIA labs in the USA.
He mentioned that Biosite sells 11 million BNP tests per year. And that the RAMP 200 can do 6 tests and has high throughput unlike the Biosite Triage tester.
Some very exciting times ahead.